Din 6935 Standard Pdf.epubl UPD
Given the wide array of UVC devices marketed for disinfection of air, water and solid surfaces, the lack of uniform performance standards and the highly variable degree of research, development and validation testing that is performed on different devices, the IUVA urges consumers to exercise caution when selecting equipment and look for evidence of third party testing as well as certification of device materials and electrical components by well-known organizations such as NSF, UL, CSA, DVGW-OVGW or other international requirements as applicable.
Din 6935 Standard Pdf.epubl UPD
For UVC devices designed to inactivate air and solid surfaces in the healthcare industry, members of IUVA are working diligently with other national standards organizations in the lighting and healthcare industry to develop disinfection testing standards[x]. The goal is to develop guidance that will help healthcare providers world-wide choose the best possible technologies for their institutions to use in the fight against multiple drug resistant organisms and other pathogens[xi], like the COVID-19 virus.
This standard contributes to the following Sustainable Development Goals: 6 Clean Water and Sanitation 8 Decent Work and Economic Growth 9 Industry, Innovation and Infrastructure 11 Sustainable Cities and Communities 12 Responsible Consumption and Production 13 Climate Action Buy this standard en Format Language std 1 124 PDF + ePub English std 2 124 Paper English CHF124 Buy
Buy this standard Life cycle Previously Withdrawn ISO 6935-2:2015 Now Published ISO 6935-2:2019 Stage: 60.60 00 Preliminary 10 Proposal 10.99 2016-10-21 New project approved 20 Preparatory 20.00 2016-10-21 New project registered in TC/SC work programme 20.20 2017-03-23 Working draft (WD) study initiated 20.99 2017-08-09 WD approved for registration as CD 30 Committee 30.00 2017-08-09 Committee draft (CD) registered 30.20 2017-08-10 CD study initiated 30.60 2017-10-07 Close of comment period 30.99 2017-11-20 CD approved for registration as DIS 40 Enquiry 40.00 2018-05-17 DIS registered 40.20 2018-07-19 DIS ballot initiated: 12 weeks 40.60 2018-10-12 Close of voting 40.99 2018-12-03 Full report circulated: DIS approved for registration as FDIS 50 Approval 50.00 2019-05-07 Final text received or FDIS registered for formal approval 50.20 2019-06-25 Proof sent to secretariat or FDIS ballot initiated: 8 weeks 50.60 2019-08-21 Close of voting. Proof returned by secretariat 60 Publication 60.00 2019-08-21 International Standard under publication 60.60 2019-10-03 International Standard published 90 Review 90.20 International Standard under systematic review 90.60 Close of review 90.92 International Standard to be revised 90.93 International Standard confirmed 90.99 Withdrawal of International Standard proposed by TC or SC 95 Withdrawal 95.99 Withdrawal of International Standard Got a question?Check out our FAQs
Patients were randomised at secondary care sites in the United Kingdom and Switzerland between January 2013 and September 2016, with 1:1 stratified allocation: 1,029 to standard of care (SOC) and 1,032 to SOC+RT. No masking of the treatment allocation was employed. A total of 1,939 had metastatic burden classifiable, with 42% low burden and 58% high burden, balanced by treatment allocation. Intention-to-treat (ITT) analyses used Cox regression and flexible parametric models (FPMs), adjusted for stratification factors age, nodal involvement, the World Health Organization (WHO) performance status, regular aspirin or nonsteroidal anti-inflammatory drug (NSAID) use, and planned docetaxel use. QoL in the first 2 years on trial was assessed using prospectively collected patient responses to QLQ-30 questionnaire.
Data Availability: Data will be available to successful applications for clearly specified research projects following the MRC CTU at UCL standard data sharing processes: -research/other-research-policy/data-sharing/ Discussion with the trial team is encouraged to determine whether the relevant data to support the application are available. Email to: email@example.com.
External beam RT to the prostate was given as 1 of 2 schedules nominated prior to randomisation: 36 Gy in 6 consecutive weekly fractions of 6 Gy or 55 Gy in 20 daily fractions of 2.75 Gy over 4 weeks. Treatment was given with the patient supine, with a full bladder and an empty rectum. The planning target volume consisted of the prostate only with an 8-mm margin posteriorly and a 10-mm margin elsewhere. RT was to commence as soon as practicable after randomisation, and, if the patient was having docetaxel as part of standard of care (SOC), within 3 to 4 weeks after the last docetaxel dose.
All subjects answered a standardized questionnaire including age, conventional cardiovascular disease risk factors, and current medication. Arterial blood pressure (BP) was measured and anthropometric measurements were taken in a standardized manner. Laboratory investigation into two categories (a) routine investigation: renal, liver function tests and lipid profile (b) special one: oral glucose tolerance test (OGTT), fasting serum insulin, HbA1c, HOMA-IR, and serum Nesfatin-1.
Our study was approved by local ethical committee of our institute. All procedures performed in our clinical study including human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the Helsinki Declaration. All individual participants gave informed consent to be included in the study.
Chemicals were obtained from commercial sources and used without further purification, unless stated otherwise. Melting points were measured on an MQAPF 301 Apparatus and were reported uncorrected. Specific rotations were measured on an ADP 220 Bellingham + Stanley Ltd. polarimeter. NMR spectra were recorded at 400 MHz (BRUKER AVANCE DRX 400) or 200 MHz (BRUKER AVANCE DRX 200) for 1H and 100 MHz or 50 MHz for 13C in CDCl3 or DMSO-d6 and were reported in ppm with TMS or residual solvent for internal standard.